RxIndia
Loading clinical data...
Loading clinical data...
Authoritative Clinical Reference
| Parameter | Detail |
|
Starting dose
|
10 mg once daily |
|
Titration
|
If blood pressure target is not achieved after a minimum of 2 weeks, increase to 20 mg once daily |
|
Usual maintenance dose
|
10–20 mg once daily |
|
Maximum dose
|
20 mg once daily |
|
Key clinical notes
|
• Administer at least 15 minutes before a meal at the same time each day, preferably in the morning; food taken simultaneously can increase bioavailability by up to 4-fold, leading to unpredictable drug levels — hence the pre-meal recommendation ensures consistent absorption
• Avoid grapefruit or grapefruit juice during therapy (CYP3A4 inhibition increases lercanidipine exposure)
• Lercanidipine is a third-generation dihydropyridine CCB with high lipophilicity and high vascular selectivity; it partitions into cell membranes and produces a gradual onset and prolonged duration of action (true 24-hour coverage with once-daily dosing)
• Compared to amlodipine, lercanidipine causes significantly less ankle oedema — this is attributed to its more balanced effect on precapillary arteriolar and postcapillary venular tone, reducing transcapillary hydrostatic pressure gradient
• Reflex tachycardia is minimal due to gradual onset of vasodilation
• May be used as monotherapy or combined with ACE inhibitors, ARBs, beta-blockers, or thiazide diuretics for enhanced blood pressure control
• No abrupt withdrawal effect; however, gradual dose reduction is prudent in patients on high doses
• Lercanidipine is metabolised extensively by hepatic CYP3A4 — significant interactions with strong CYP3A4 inhibitors and inducers must be anticipated
• Not the first-choice CCB in Indian practice (amlodipine remains the most widely prescribed); however, lercanidipine is preferred when amlodipine-related peripheral oedema limits adherence
• Alcohol should be avoided as it potentiates the vasodilatory and hypotensive effects
|
| eGFR (mL/min/1.73 m²) | Recommendation |
|
≥ 30
|
No dose adjustment required; standard dosing applies |
|
< 30 (including dialysis patients)
|
Use with caution; initiate at 10 mg daily and do not increase to 20 mg unless under specialist supervision; monitor blood pressure closely for excessive hypotension |
| Child-Pugh Class | Recommendation |
|
A (Mild)
|
No dose adjustment required; standard starting dose of 10 mg once daily |
|
B (Moderate)
|
Use with caution; start at 10 mg once daily; avoid uptitration to 20 mg unless clinically essential and under close monitoring; hepatic CYP3A4 metabolism is impaired, leading to increased drug exposure |
|
C (Severe)
|
Avoid use; significantly increased bioavailability and drug exposure expected; no safety data available |
| Parameter | Detail |
|
Overall safety
|
Contraindicated; animal studies have shown reproductive toxicity; no adequate human data available |
|
Preferred alternatives in Indian obstetric practice
|
Methyldopa (first line); labetalol; nifedipine extended-release (the only dihydropyridine CCB with established safety in pregnancy) |
|
When it may be used
|
Should not be used during pregnancy at any stage |
|
Monitoring if inadvertently exposed
|
Monitor maternal blood pressure, fetal growth, and fetal well-being; switch to a safer alternative immediately upon confirmation of pregnancy |
| Parameter | Detail |
|
Compatibility with breastfeeding
|
Not recommended; it is unknown whether lercanidipine is excreted in human breast milk (high lipophilicity suggests probable excretion) |
|
Expected drug levels in milk
|
Unknown; likely low to moderate based on physicochemical properties |
|
Preferred alternatives
|
Nifedipine extended-release (established lactation safety data), labetalol, or amlodipine (limited but reassuring data) |
|
Monitoring in infant
|
If exposure occurs, observe infant for hypotension (lethargy, poor feeding, excessive sleepiness) and poor weight gain |
| Interacting Drug/Class | Effect / Mechanism | Action |
|
Strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin)
|
Marked increase in lercanidipine plasma levels → excessive hypotension and toxicity; lercanidipine is almost entirely metabolised by CYP3A4 |
Contraindicated — avoid concurrent use
|
|
Ciclosporin
|
Mutual elevation of plasma concentrations of both drugs (lercanidipine increases ciclosporin AUC, ciclosporin inhibits CYP3A4 and P-gp) |
Contraindicated — avoid concurrent use
|
|
Grapefruit juice
|
Inhibition of intestinal CYP3A4 → increased lercanidipine bioavailability by up to 3-fold |
Avoid grapefruit or grapefruit juice during therapy
|
|
CYP3A4 inducers (rifampicin, phenytoin, carbamazepine, phenobarbital, St John’s Wort)
|
Markedly reduced lercanidipine plasma levels → potential loss of antihypertensive efficacy |
Avoid combination; if unavoidable, blood pressure monitoring is essential and alternative antihypertensive may be needed
|
|
Verapamil / Diltiazem (non-dihydropyridine CCBs)
|
Additive negative inotropic effect and vasodilation; diltiazem also inhibits CYP3A4 increasing lercanidipine levels |
Avoid concurrent use
|
| Interacting Drug/Class | Effect | Action |
|
Beta-blockers (metoprolol, atenolol, bisoprolol)
|
Additive antihypertensive effect; combination is therapeutically rational but may increase risk of hypotension or bradycardia | Monitor blood pressure and heart rate; generally well tolerated in combination |
|
Moderate CYP3A4 inhibitors (fluconazole, erythromycin, verapamil — see also Major section)
|
Moderate increase in lercanidipine exposure | Monitor for excessive hypotension; consider using 10 mg dose without uptitration |
|
Digoxin
|
Lercanidipine may increase digoxin levels | Monitor serum digoxin levels; watch for signs of digoxin toxicity (nausea, visual disturbances, arrhythmias) |
|
Cimetidine (≤ 800 mg/day)
|
Modest increase in lercanidipine bioavailability | Monitor blood pressure; usually clinically insignificant at standard cimetidine doses |
|
Simvastatin
|
Co-administration may increase simvastatin exposure when both are metabolised via CYP3A4 | When combined, administer lercanidipine in the morning and simvastatin in the evening to minimise interaction; monitor for statin-related myopathy |
|
Midazolam
|
Lercanidipine may modestly increase oral midazolam absorption | Monitor for excessive sedation if co-administered |
|
ACE inhibitors / ARBs
|
Additive antihypertensive effect; rational combination therapy for hypertension | Monitor blood pressure; no pharmacokinetic interaction; FDC with enalapril available in some markets |
|
Alcohol
|
Potentiates vasodilatory hypotension | Advise limiting alcohol intake during therapy |
|
Anti-TB drugs (rifampicin — see also Major section; isoniazid — CYP inhibitor)
|
Rifampicin is a strong CYP3A4 inducer (see Major); isoniazid may modestly inhibit CYP enzymes | If on rifampicin-based ATT, consider an alternative antihypertensive such as amlodipine (less CYP3A4 dependent) or a non-CCB class |
| Timing | Parameters |
|
Baseline (before initiation)
|
Blood pressure (sitting and standing), heart rate, hepatic function (LFTs — given CYP3A4 dependence), renal function (creatinine, eGFR), review concomitant medications for CYP3A4 interactions |
|
After initiation / dose change
|
Blood pressure within 2 weeks; assess for peripheral oedema, dizziness, or symptomatic hypotension |
|
Long-term (stable patients)
|
Blood pressure every 3–6 months; periodic hepatic function if on long-term therapy; assessment for peripheral oedema and gingival hyperplasia; review concomitant medication list for new CYP3A4 interactions at each visit |
| Strength | Approximate Price per Tablet (INR) |
| 10 mg | ₹5–8 per tablet |
| 20 mg | ₹9–13 per tablet |
This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.
Help us improve our clinical database for the medical community.